The discovery by both teams of a novel TDP‐43‐dependent cryptic splicing event in a bona fide FTD‐ALS risk gene now opens up many exciting new directions for validating UNC13A as a biomarker and therapeutic target in ALS and FTD (discussed below). The gene discussed is UNC13A; the disease is frontotemporal dementia.